Fig. 1From: Novel antidotes for target specific oral anticoagulantsIdarucizumab binds and inactivates dabigatran. Idarucizumab is the first-in-class dabigatran-specific antidote. It is a humanized monoclonal antibody fragment [Fab] that binds specifically to and inactivates dabigatranBack to article page